StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

GeneDx r&d expenses

Research and development expenses are spending on new products and technology.

GeneDx's R&D Expenses for the twelve months ending Jun 30, 2026 was $83.83M, up 64.7% year over year. For fiscal 2025 it was $72.03M, up 57.5% from the year before. The highest annual figure on record is $105.16M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.03M+57.5%
FY2024Dec 31, 2024$45.72M-21.5%
FY2023Dec 31, 2023$58.27M-32.4%
FY2022Dec 31, 2022$86.20M-18.0%
FY2021Dec 31, 2021$105.16M+44.7%
FY2020Dec 31, 2020$72.70M+108.2%
FY2019Dec 31, 2019$34.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.66M+30.4%
Q1 FY2026Mar 31, 2026$19.80M+57.5%
Q4 FY2025Dec 31, 2025$24.54M+111.8%
Q3 FY2025Sep 30, 2025$19.83M+70.0%
Q2 FY2025Jun 30, 2025$15.08M+38.3%
Q1 FY2025Mar 31, 2025$12.58M+8.7%
Q4 FY2024Dec 31, 2024$11.59M-5.4%
Q3 FY2024Sep 30, 2024$11.67M-18.4%
Q2 FY2024Jun 30, 2024$10.90M-36.4%
Q1 FY2024Mar 31, 2024$11.57M-20.7%
Q4 FY2023Dec 31, 2023$12.25M-49.7%
Q3 FY2023Sep 30, 2023$14.29M+7.0%
Q2 FY2023Jun 30, 2023$17.14M-36.9%
Q1 FY2023Mar 31, 2023$14.59M-31.5%
Q4 FY2022Dec 31, 2022$24.37M+9.5%
Q3 FY2022Sep 30, 2022$13.35M-25.1%
Q2 FY2022Jun 30, 2022$27.17M+127.3%
Q1 FY2022Mar 31, 2022$21.32M-59.9%
Q4 FY2021Dec 31, 2021$22.25M-28.6%
Q3 FY2021Sep 30, 2021$17.83M-6.6%
Q2 FY2021Jun 30, 2021$11.95M+27.7%
Q1 FY2021Mar 31, 2021$53.13M+305.7%
Q4 FY2020Dec 31, 2020$31.16M–
Q3 FY2020Sep 30, 2020$19.08M–
Q2 FY2020Jun 30, 2020$9.36M–
Q1 FY2020Mar 31, 2020$13.10M–

More GeneDx figures

See a number that looks wrong?